Kieran Engels is CEO and Co-Founder of Seuss+, and has spent 20+ years inside clinical development – as an operator, a program leader, and now a governance partner for biotech and pharmaceutical sponsors. These perspectives examine the structural patterns that decide whether a clinical program holds under pressure: how vendor-sponsor partnerships actually function, where governance quietly breaks down, and why most execution failures are visible in the operating model long before they appear on a timeline.
The through-line across this work is simple. Clinical program outcomes are not primarily a function of protocol complexity or site performance. They are a function of the leadership choices made before a single patient is enrolled: how vendors are selected, how escalation is defined, how decision rights are structured, and whether the sponsor is equipped to ask the questions that a CRO will not volunteer. Kieran writes for clinical operations leaders, biotech executives, and sponsor governance teams who are making those choices in real time, usually with incomplete information and compressed timelines.
Key Takeaways from These Perspectives
- What looks like vendor failure is almost always visible in the governance model before it shows up in the data.
- Vendor selection is a leadership decision, not a procurement exercise. The wrong structure guarantees the wrong outcome.
- Speed without control is not acceleration. It is crash risk being priced as progress.
- Sponsor-side oversight fails when escalation paths are informal. It holds when they are contractual.
- The sponsors who avoid late-stage surprises are the ones who invest in governance design early, not the ones who react faster.
“Governance is the design system. Everything else is execution inside that system.”
Vendor selection is a leadership decision
Most sponsor organizations treat CRO selection as a procurement workflow: scope the work, solicit bids, score the responses, sign the MSA. That framing is the first leadership failure. A CRO is not a line item. It is the operating system through which an entire clinical program will be delivered, and the selection process is the only moment the sponsor holds genuine structural leverage. The questions asked before signature determine what can be asked after. The teams that get this right treat vendor selection as a governance decision with procurement support, not the other way around, and they staff it accordingly.
Read more on this topic: Vendor Strategy →
Governance is the oversight model, not the status call
Weekly status calls are not governance. Governance is the contractual and operational structure that decides who sees what data, who escalates, who has decision rights, and how disagreements are resolved before they become delays. When sponsors describe a CRO relationship as “collaborative” without being able to name the escalation ladder, the governance model does not exist, and the trial is running on goodwill. Goodwill is a fine lubricant and a terrible load-bearing structure. It holds until the first difficult conversation, at which point the absence of defined rights and paths becomes the problem everyone has to solve while also trying to stay on timeline.
Read more on this topic: Governance & Oversight →
Speed without control is not acceleration
Every sponsor feels pressure to move faster. Few stop to ask what “faster” is actually producing. A trial that moves fast but loses data integrity is not ahead of schedule. A program that accelerates but cannot trace its decisions is not making progress. Speed without control is crash risk being optimistically priced as velocity. The sponsors who deliver on timeline are the ones who treat pace and accountability as one problem, not two, and who refuse to sacrifice the second in pursuit of the first.
Read more on this topic: Execution & Operations →
Execution failure is not scientific failure
Most clinical program failures are written up as scientific – the drug did not work, the endpoint was not met, the population was too narrow. Many of those failures are execution failures wearing scientific clothing: vendors operating without clear requirements, data handoffs that lost fidelity, decisions that were never documented, signals that were flagged and then filed. When the structure between intent and delivery is weak, the science takes the blame. The work of governance is to stop offering the science as cover for structural failures it did not cause.
Read more on this topic: Accountability & Leadership →
The industry backdrop
These perspectives sit inside a development environment that has become harder, not easier, over the last decade. Trials are larger, protocols are more complex, regulatory expectations are more granular, and the pool of sites and investigators capable of running them is not expanding fast enough to match demand. The numbers below frame why the leadership-level choices Kieran writes about are not academic – they compound across every program a sponsor runs.
Frequently Asked Questions
Who is Kieran Engels?+
Kieran Engels is CEO and Co-Founder of Seuss+, an independent strategy and execution consultancy based in Amsterdam. She has spent 20+ years in clinical development, working with biotech and pharmaceutical sponsors on the governance structures between strategy and vendor delivery.
What does Kieran write about?+
Kieran writes about the structural patterns inside clinical development that decide program outcomes: vendor selection, governance design, execution accountability, and partnership integrity between sponsors and CROs.
Who is this work for?+
Biotech and pharmaceutical leaders making vendor and governance decisions. That means heads of clinical operations, development leaders, sponsor executives, and boards overseeing clinical-stage programs.
How often are new perspectives published?+
Roughly one long-form essay per month, plus occasional shorter pieces responding to industry events or regulatory developments.
Can Kieran speak at our event or on our podcast?+
Yes. Kieran accepts a limited number of speaking and podcast engagements each year on vendor governance, execution accountability, and clinical development oversight. Requests go through the media page.